ARH-I is expressed in normal epithelial cells, while it is downregulated or lost in more than 60% of ovarian cancer cases due to loss of heterozygosity, DNA methylation, transcriptional regulation, and shortened mRNA half-life but also via epigenetic mechanisms involving non-coding RNAs [30]. This evidence concerns the gene DIRAS3 and ovarian carcinoma.